Aclaris Therapeutics (NASDAQ:ACRS) Research Coverage Started at Scotiabank
Scotiabank started coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report published on Friday,Benzinga reports. The firm issued a sector outperform rating and a $15.00 price target on the biotechnology company’s stock. A number of other brokerages also recently issued reports on ACRS. BTIG Research raised shares of Aclaris Therapeutics from […]
Scotiabank started coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report published on Friday,Benzinga reports. The firm issued a sector outperform rating and a $15.00 price target on the biotechnology company’s stock. A number of other brokerages also recently issued reports on ACRS. BTIG Research raised shares of Aclaris Therapeutics from […]
